Applied DNA Sciences Files 8-K on Shareholder Votes

TL;DR

APDN filed an 8-K for shareholder votes - details TBD.

AI Summary

Applied DNA Sciences, Inc. filed an 8-K on February 14, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or outcomes, but it serves as an official notification of such events.

Why It Matters

This filing indicates that Applied DNA Sciences held a shareholder vote, which could have implications for corporate governance and future strategic decisions.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.

Key Players & Entities

• Applied DNA Sciences, Inc. (company) — Registrant
• February 14, 2025 (date) — Date of Report
• Delaware (jurisdiction) — State of Incorporation
• 50 Health Sciences Drive Stony Brook, New York 11790 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar

Filing Documents

• tm256728d1_8k.htm (8-K) — 24KB
• 0001104659-25-014243.txt ( ) — 192KB
• apdn-20250214.xsd (EX-101.SCH) — 3KB
• apdn-20250214_lab.xml (EX-101.LAB) — 33KB
• apdn-20250214_pre.xml (EX-101.PRE) — 22KB
• tm256728d1_8k_htm.xml (XML) — 3KB

07

Item 5.07 Submission of Matters to a Vote of Security Holders. On February 14, 2025, Applied DNA Sciences, Inc. (the "Company") reconvened its special meeting of stockholders (the "Special Meeting") which was originally held on January 23, 2025 and adjourned. At the Special Meeting, an aggregate of 16,020,694 shares of the Company's common stock ("Common Stock") were present in person or by proxy and entitled to vote, which did not constitute a quorum determined in accordance with the Company's By-Laws, which requires one-third of the Company's issued and outstanding shares of Common Stock. Accordingly, no action was taken with respect to the proposal presented at the Special Meeting, and the Special Meeting was adjourned for a second time until February 28, 2025, at 11:00 a.m. in order to permit additional solicitation of stockholders and to allow stockholders additional time to vote on the sole proposal under consideration at the Special Meeting. As previously reported on its Form 8-K filed on October 31, 2024, the Company closed on such date a registered direct public offering and concurrent private placement (the "Offering") of common stock, series C and D common stock purchase warrants (the "Series Warrants") and placement agent warrants ("Placement Agent Warrants", and, with the Series Warrants, the "Private Placement Warrants"). The Private Placement Warrants will only be exercisable upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market (the "Warrant Stockholder Approval"). Further, pursuant to the terms of the Securities Purchase Agreement entered into in connection with the Offering, if the Company does not obtain Warrant Stockholder Approval at the Special Meeting, as adjourned, it will be obligated to call a subsequent stockholder meeting to seek to obtain Warrant Stockholder Approval.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 14, 2025 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR